Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Guidelines

Recommendations on screening for prostate cancer with the prostate-specific antigen test

Neil Bell, Sarah Connor Gorber, Amanda Shane, Michel Joffres, Harminder Singh, James Dickinson, Elizabeth Shaw, Lesley Dunfield, Marcello Tonelli and Canadian Task Force on Preventive Health Care
CMAJ November 04, 2014 186 (16) 1225-1234; DOI: https://doi.org/10.1503/cmaj.140703
Neil Bell
Department of Family Medicine (Bell), University of Alberta, Edmonton, Alta.; Public Health Agency of Canada (Connor Gorber, Shane, Dunfield), Ottawa, Ont.; Faculty of Health Sciences (Joffres), Simon Fraser University, Burnaby, BC; Departments of Internal Medicine and Community Health Sciences (Singh), University of Manitoba, Winnipeg, Man.; Departments of Family Medicine and Community Health Sciences (Dickinson) and Office of the Associate Dean — Research (Tonelli), University of Calgary, Calgary, Alta.; Department of Family Medicine (Shaw), McMaster University, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Connor Gorber
Department of Family Medicine (Bell), University of Alberta, Edmonton, Alta.; Public Health Agency of Canada (Connor Gorber, Shane, Dunfield), Ottawa, Ont.; Faculty of Health Sciences (Joffres), Simon Fraser University, Burnaby, BC; Departments of Internal Medicine and Community Health Sciences (Singh), University of Manitoba, Winnipeg, Man.; Departments of Family Medicine and Community Health Sciences (Dickinson) and Office of the Associate Dean — Research (Tonelli), University of Calgary, Calgary, Alta.; Department of Family Medicine (Shaw), McMaster University, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Shane
Department of Family Medicine (Bell), University of Alberta, Edmonton, Alta.; Public Health Agency of Canada (Connor Gorber, Shane, Dunfield), Ottawa, Ont.; Faculty of Health Sciences (Joffres), Simon Fraser University, Burnaby, BC; Departments of Internal Medicine and Community Health Sciences (Singh), University of Manitoba, Winnipeg, Man.; Departments of Family Medicine and Community Health Sciences (Dickinson) and Office of the Associate Dean — Research (Tonelli), University of Calgary, Calgary, Alta.; Department of Family Medicine (Shaw), McMaster University, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Joffres
Department of Family Medicine (Bell), University of Alberta, Edmonton, Alta.; Public Health Agency of Canada (Connor Gorber, Shane, Dunfield), Ottawa, Ont.; Faculty of Health Sciences (Joffres), Simon Fraser University, Burnaby, BC; Departments of Internal Medicine and Community Health Sciences (Singh), University of Manitoba, Winnipeg, Man.; Departments of Family Medicine and Community Health Sciences (Dickinson) and Office of the Associate Dean — Research (Tonelli), University of Calgary, Calgary, Alta.; Department of Family Medicine (Shaw), McMaster University, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harminder Singh
Department of Family Medicine (Bell), University of Alberta, Edmonton, Alta.; Public Health Agency of Canada (Connor Gorber, Shane, Dunfield), Ottawa, Ont.; Faculty of Health Sciences (Joffres), Simon Fraser University, Burnaby, BC; Departments of Internal Medicine and Community Health Sciences (Singh), University of Manitoba, Winnipeg, Man.; Departments of Family Medicine and Community Health Sciences (Dickinson) and Office of the Associate Dean — Research (Tonelli), University of Calgary, Calgary, Alta.; Department of Family Medicine (Shaw), McMaster University, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Dickinson
Department of Family Medicine (Bell), University of Alberta, Edmonton, Alta.; Public Health Agency of Canada (Connor Gorber, Shane, Dunfield), Ottawa, Ont.; Faculty of Health Sciences (Joffres), Simon Fraser University, Burnaby, BC; Departments of Internal Medicine and Community Health Sciences (Singh), University of Manitoba, Winnipeg, Man.; Departments of Family Medicine and Community Health Sciences (Dickinson) and Office of the Associate Dean — Research (Tonelli), University of Calgary, Calgary, Alta.; Department of Family Medicine (Shaw), McMaster University, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Shaw
Department of Family Medicine (Bell), University of Alberta, Edmonton, Alta.; Public Health Agency of Canada (Connor Gorber, Shane, Dunfield), Ottawa, Ont.; Faculty of Health Sciences (Joffres), Simon Fraser University, Burnaby, BC; Departments of Internal Medicine and Community Health Sciences (Singh), University of Manitoba, Winnipeg, Man.; Departments of Family Medicine and Community Health Sciences (Dickinson) and Office of the Associate Dean — Research (Tonelli), University of Calgary, Calgary, Alta.; Department of Family Medicine (Shaw), McMaster University, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lesley Dunfield
Department of Family Medicine (Bell), University of Alberta, Edmonton, Alta.; Public Health Agency of Canada (Connor Gorber, Shane, Dunfield), Ottawa, Ont.; Faculty of Health Sciences (Joffres), Simon Fraser University, Burnaby, BC; Departments of Internal Medicine and Community Health Sciences (Singh), University of Manitoba, Winnipeg, Man.; Departments of Family Medicine and Community Health Sciences (Dickinson) and Office of the Associate Dean — Research (Tonelli), University of Calgary, Calgary, Alta.; Department of Family Medicine (Shaw), McMaster University, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcello Tonelli
Department of Family Medicine (Bell), University of Alberta, Edmonton, Alta.; Public Health Agency of Canada (Connor Gorber, Shane, Dunfield), Ottawa, Ont.; Faculty of Health Sciences (Joffres), Simon Fraser University, Burnaby, BC; Departments of Internal Medicine and Community Health Sciences (Singh), University of Manitoba, Winnipeg, Man.; Departments of Family Medicine and Community Health Sciences (Dickinson) and Office of the Associate Dean — Research (Tonelli), University of Calgary, Calgary, Alta.; Department of Family Medicine (Shaw), McMaster University, Hamilton, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Department of Family Medicine (Bell), University of Alberta, Edmonton, Alta.; Public Health Agency of Canada (Connor Gorber, Shane, Dunfield), Ottawa, Ont.; Faculty of Health Sciences (Joffres), Simon Fraser University, Burnaby, BC; Departments of Internal Medicine and Community Health Sciences (Singh), University of Manitoba, Winnipeg, Man.; Departments of Family Medicine and Community Health Sciences (Dickinson) and Office of the Associate Dean — Research (Tonelli), University of Calgary, Calgary, Alta.; Department of Family Medicine (Shaw), McMaster University, Hamilton, Ont.
  • For correspondence: info@canadiantaskforce.ca
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading
Submit a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
References
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Minimum 7 characters.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'. Minimum 12 characters.
Your organization, institution's or residential address.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

  • RE: Prostate cancer screening and rectal exam
    David K Thompson
    Posted on: 10 January 2019
  • Prostate screening: biopsy, injury and tumor progression.
    Johannes P van Netten
    Posted on: 07 January 2015
  • PSA
    Ernst R Snyman
    Posted on: 28 November 2014
  • On the beneficial effects of PSA testing
    Francois M Mai
    Posted on: 26 November 2014
  • Recommendations about prostate cancer screening: Has the task enough force?
    Alain Braillon
    Posted on: 17 November 2014
  • Posted on: (10 January 2019)
    Page navigation anchor for RE: Prostate cancer screening and rectal exam
    RE: Prostate cancer screening and rectal exam
    • David K Thompson, family physician, None

    It would be helpful if the task force would make a specific statement with regards to the utility of rectal examination alone as a tool to decide whether further investigation is warranted,

    Competing Interests: None declared.
  • Posted on: (7 January 2015)
    Page navigation anchor for Prostate screening: biopsy, injury and tumor progression.
    Prostate screening: biopsy, injury and tumor progression.
    • Johannes P van Netten, Biomedicine
    • Other Contributors:

    In 2014 the Canadian Task Force for Preventative Medicine reported in your journal that, for prostate screening "the harms outweigh the benefits" (1). In addition, it was recently reported that pathological differentiation of insignificant prostate cancer in the early stages can be inaccurate, compounding the harms (2). We propose there may be a common denominator underlying both issues.

    In breast cancer, needle...

    Show More

    In 2014 the Canadian Task Force for Preventative Medicine reported in your journal that, for prostate screening "the harms outweigh the benefits" (1). In addition, it was recently reported that pathological differentiation of insignificant prostate cancer in the early stages can be inaccurate, compounding the harms (2). We propose there may be a common denominator underlying both issues.

    In breast cancer, needle biopsies increase the likelihood of cancer cell spreading by 50% over women that had immediate surgical removal of the tumor (3) Also, radical prostatectomy reduces mortality among men with localized prostate cancer (4). Prostate biopsies may take 12 or more needles. This results in significant damage to an organ as small as a walnut. For most patients this inflammatory period causes no lasting problems and residual dormant prostate cancer cells remain dormant, in some patients it may be problematic. Dormant cancer cells carrying epidermal growth factor (EGF) related surface receptors such as Her2 may become aggressive during the wound healing inflammation. Thus an association between benign prostate cancer, inflammation and high-grade prostate cancer has already been noted (5).

    Trauma induces many growth factors including EGF, Heparin-binding (HB - EGF, Nerve growth factor (NGF) among many others. These factors can stimulate growth and migration behavior of cells carrying the appropriate receptors. This is supported by the higher incidence of Her2 and EGFR positive expression in metastatic prostate cancer compared to primary cancer 6-8). Also, in receptor positive patients the initial biopsy analysis (2) may have correctly identified non-aggressive cancer that became subsequently activated during the wounding. Thus, at prostatectomy, these tumors would be found to have progressed, resulting in an apparent inaccurate initial diagnosis.

    Finally, a reduction in breast cancer relapses has been observed with perioperative non-steroidal anti-inflammatories (9). Such drugs may also be effective when used during injury recovery after biopsies.

    References

    1.Cancer Research UK, Screening for Prostate Cancer, 2014.

    2.Sonn GA, Natarajan S, Margolis DJA, et al. Targeted Biopsy in the Detection of Prostate Cancer Using an Office Based Magnetic Resonance Ultrasound Fusion Device. J Urol 2013; 189: 86-92.

    3.Hansen NM, Xing Ye, Baiba J, et al. Manipulation of the primary breast tumor and the incidence of sentinel node metastases from invasive breast cancer. Arch Surg 2004; 139: 634-640.

    4.Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352:1977-84.

    5.Gurel B, Lucia MS, Thompson IM Jr. et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2014; 23: 847-56.

    6.Carlsson J, Shen L, Xiang J, et al. Tendencies for higher co- expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors. Oncol Lett 2013; 5; 208-214.

    7.Di Lorenzo G, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438-3452.

    8.Carles J, Lloreta J, Salido M, et al. Her-2/neu expression in prostate cancer: a dynamic process? Clin Cancer Res 2004; 10: 4742-4745.

    9.Retsky M, Demicheli R, Hrushesky WJ, et al. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: a new finding. Curr Med Chem 2013: 20; 4163-76.

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
  • Posted on: (28 November 2014)
    Page navigation anchor for PSA
    PSA
    • Ernst R Snyman, MD

    I refer to the article published in the CMAJ of November 4 2014. Vol.186. I was shocked and saddened to read your article on this important test. Why on earth do we always have to go back to the start in medicine. Is it the need to be seen publishing something , because I just cannot believe that any body would come up with such a ridiculous , short sighted and in my view , irresponsible recommendation. The PSA test and m...

    Show More

    I refer to the article published in the CMAJ of November 4 2014. Vol.186. I was shocked and saddened to read your article on this important test. Why on earth do we always have to go back to the start in medicine. Is it the need to be seen publishing something , because I just cannot believe that any body would come up with such a ridiculous , short sighted and in my view , irresponsible recommendation. The PSA test and more so ,serial testing of PSA, is a valuable and essential clinical test. It is what is being done with the information once a problem was identified, where the harm might be done. Dr E R Snyman. Camrose, Alberta

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
  • Posted on: (26 November 2014)
    Page navigation anchor for On the beneficial effects of PSA testing
    On the beneficial effects of PSA testing
    • Francois M Mai, Retired physician

    I am deeply disappointed with the recommendations of the task force on the use of the PSA test as a screening test for cancer. I am a seventy nine year old man and an example of a patient in whom the PSA test was clearly beneficial.

    For reasons unrelated to the PSA test, I changed my family physician (FP) in 2013. Although I was symptomless my new FP ordered the PSA test in February 2014 (it had not been done p...

    Show More

    I am deeply disappointed with the recommendations of the task force on the use of the PSA test as a screening test for cancer. I am a seventy nine year old man and an example of a patient in whom the PSA test was clearly beneficial.

    For reasons unrelated to the PSA test, I changed my family physician (FP) in 2013. Although I was symptomless my new FP ordered the PSA test in February 2014 (it had not been done previously) and found it to be very high (41 ng/ml). Biopsy revealed an aggressive form of cancer of the prostate (Gleason grade 9) and CT scan showed pelvic lymph nodes. Bone scan was negative for metastases. I am now on anti-androgen medication and the cancer is in remission.

    If my former FP had carried out PSA testing my cancer might have been detected before the cancer had spread to the lymph nodes hence been potentially curable. I am disappointed that he did not discuss with me the pros and cons of the PSA test and took it upon himself to make that decision without consulting me. I am thankful that my new FP ordered the test.

    The problem is not with the PSA test itself; it is with the way the test results are interpreted and managed. Clearly, interventions such as biopsy, prostatectomy and radiotherapy are potentially harmful hence it is not appropriate to carry out such procedures on a man with low probability of a lethal condition.

    I plead for continued use of the PSA test, open discussion with patients about the interpretation of the results and more use of watchful waiting in men whose test results are equivocal.

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
  • Posted on: (17 November 2014)
    Page navigation anchor for Recommendations about prostate cancer screening: Has the task enough force?
    Recommendations about prostate cancer screening: Has the task enough force?
    • Alain Braillon, Consultant

    The Canadian Task Force on Preventive Health Care has updated its recommendation about screening for prostate cancer.[1] This deserves comments

    First, the Task Force has waited 20 year to do so.[2] This is very poor practice.[3]

    Second, the Task Force failed to provide an information leaflet for the patient to assist clinicians in the "thoughtful discussion with the patient about the balance between...

    Show More

    The Canadian Task Force on Preventive Health Care has updated its recommendation about screening for prostate cancer.[1] This deserves comments

    First, the Task Force has waited 20 year to do so.[2] This is very poor practice.[3]

    Second, the Task Force failed to provide an information leaflet for the patient to assist clinicians in the "thoughtful discussion with the patient about the balance between unclear benefits and substantial harms".[1] Moreover, the Task Force has no tools to monitor the implementation of its recommendation. Such pitfalls explain why previous recommendations were useless.[4]

    Sadly, with this new recommendation, Canada mimics France. Accordingly, similar results can be expected.[5] Indeed, "Insanity: doing the same thing over and over again and expecting different results."(Einstein)

    References

    [1] Canadian Task Force on Preventive Health Care. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ 2014. Online October 27. DOI:10.1503

    /cmaj.140703.

    [2] Canadian Task Force on the Periodic Health Examination. Screening for prostate cancer. In: The Canadian guide to clinical preventive health care. Ottawa: Canada Communication Group;1994:812.

    [3] Braillon A, Gignon M, Dubois G. G-I-N must adopt the WHISKY statement. Qual Saf Health Care 2005;14:391.

    [4] Gignon M, Braillon A, Chaine FX, Dubois G. [Mass screening guidelines for prostate cancer: Should they be utilized in France?]. Can J Public Health 2007 -;98:212-6

    [5] Braillon A.Prostate-specific antigen testing in france. JAMA Intern Med 2013 25;173:2014.

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 186 (16)
CMAJ
Vol. 186, Issue 16
4 Nov 2014
  • Table of Contents
  • Index by author

Article extras

  • Ligne directrice (français)
  • Clinician FAQ
  • FAQ pour cliniciens
  • 1000-Person Tool
  • Outil de dépistage auprès de 1000 personnes
  • More implementation support tools >>

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Recommendations on screening for prostate cancer with the prostate-specific antigen test
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Recommendations on screening for prostate cancer with the prostate-specific antigen test
Neil Bell, Sarah Connor Gorber, Amanda Shane, Michel Joffres, Harminder Singh, James Dickinson, Elizabeth Shaw, Lesley Dunfield, Marcello Tonelli, Canadian Task Force on Preventive Health Care
CMAJ Nov 2014, 186 (16) 1225-1234; DOI: 10.1503/cmaj.140703

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Recommendations on screening for prostate cancer with the prostate-specific antigen test
Neil Bell, Sarah Connor Gorber, Amanda Shane, Michel Joffres, Harminder Singh, James Dickinson, Elizabeth Shaw, Lesley Dunfield, Marcello Tonelli, Canadian Task Force on Preventive Health Care
CMAJ Nov 2014, 186 (16) 1225-1234; DOI: 10.1503/cmaj.140703
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Methods
    • Benefits of PSA screening
    • Harms of screening
    • Benefits and harms of treatment
    • Recommendations
    • Considerations for implementation
    • Other guidelines
    • Other screening tests
    • Gaps in knowledge
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Prostate cancer screening: going beyond the clinical evidence
  • Highlights
  • PubMed
  • Google Scholar

Cited By...

  • Is one narrative enough? Analytical tools should match the problems they address
  • Depistage du cancer au Canada: Ce qui est in, ce qui est out, ce qui sen vient
  • Cancer screening in Canada: Whats in, whats out, whats coming
  • Cohort profile: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada
  • Prediction models for prostate cancer to be used in the primary care setting: a systematic review
  • Arrogance of 'but all you need is a good index finger: A narrative ethics exploration of lack of universal funding of PSA screening in Canada
  • Projected estimates of cancer in Canada in 2020
  • Age-standardized cancer-incidence trends in Canada, 1971-2015
  • Repercussions de la modification des lignes directrices pour lexamen rectal digital sur la formation des etudiants
  • Educational implications of changing the guidelines for the digital rectal examination
  • Yield of prostate cancer screening at a community based clinic in Saudi Arabia
  • Resisting recommended treatment for prostate cancer: a qualitative analysis of the lived experience of possible overdiagnosis
  • Quality of the screening process: An overlooked critical factor and an essential component of shared decision making about screening
  • Qualite du processus de depistage: Un facteur critique neglige et un element essentiel de la prise de decision partagee concernant le depistage
  • Prescribing and testing by primary care providers to assess adherence to the Choosing Wisely Canada recommendations: a retrospective cohort study
  • Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline
  • Values and preferences of men for undergoing prostate-specific antigen screening for prostate cancer: a systematic review
  • Screening: when things go wrong
  • Depistage : quand les choses tournent mal
  • Choosing guidelines to use in your practice
  • Reducing overtreatment of prostate cancer by radical prostatectomy in Eastern Ontario: a population-based cohort study
  • Choisir les guides de pratique clinique a utiliser
  • Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis
  • Knowledge translation tools in preventive health care
  • Outils dapplication des connaissances en soins de sante preventifs
  • Prendre de meilleures decisions en matiere de depistage preventif: Equilibrer bienfaits et prejudices
  • Better decision making in preventive health screening: Balancing benefits and harms
  • Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms
  • Trends in prostate biopsy in Ontario, 1992-2014: a cohort study
  • Active surveillance in Canadian men with low-grade prostate cancer
  • Adult health checkup: Update on the Preventive Care Checklist Form(C)
  • Bilan de sante chez ladulte: Mise a jour de Soins preventifs - Fiche de controle(C)
  • Prostate cancer screening: going beyond the clinical evidence
  • Google Scholar

More in this TOC Section

  • Recommendations on screening for developmental delay
  • Recommendations on screening for lung cancer
  • Recommendations on screening for colorectal cancer in primary care
Show more Guidelines

Similar Articles

Collections

  • Article Types
    • Guidelines
  • Topics
    • Cancer: prostate
    • Screening & diagnostic tests
    • Urology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire